Glycine compound

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8802679
APP PUB NO 20120184520A1
SERIAL NO

13394505

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Compounds of formula (I) defined herein exhibit VAP-1 inhibitory activity, and as a result, are useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ASTELLAS PHARMA INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Fujiyasu, Jiro Tokyo, JP 10 47
Koga, Yuji Tokyo, JP 180 2198
Neya, Masahiro Kobe, JP 26 271
Seki, Norio Tokyo, JP 38 376
Suzuki, Daisuke Tokyo, JP 271 1849
Yamaki, Susumu Tokyo, JP 16 73
Yoshihara, Kousei Tokyo, JP 12 112

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 12, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00